Section: General Medicine

Review Article

LIVER-ENRICHED TRANSCRIPTION FACTORS: KEY BIOMARKERS AND THERAPEUTIC TARGETS IN CHRONIC LIVER DISEASE

Talasila Naga Venkata Gowtham[1], Shimpra R Sharma[2]

[1]*Junior Resident, Department of General Medicine, D. Y. Patil Medical College Kolhapur, Maharashtra, India.*
[2]*Professor, Department of General Medicine, D. Y. Patil Medical College Kolhapur, Maharashtra, India.*

Received *: 02/09/2024*
Received in revised form *: 23/10/2024*
Accepted *: 07/11/2024*

Corresponding Author:
Dr. Talasila Naga Venkata Gowtham,
Junior Resident, Department of General Medicine, D. Y. Patil Medical College Kolhapur, Maharashtra, India
Email: talasilagowtham9@gmail.com

DOI: 10.70034/ijmedph.2024.4.107

Source of Support: Nil,
Conflict of Interest: None declared

Int J Med Pub Health
2024; 14 (4); 568-570

ABSTRACT

Background: Chronic liver disease (CLD) is a complex and multifaceted condition characterized by persistent liver injury, inflammation, and fibrosis, often leading to cirrhosis and its associated complications, including liver failure and hepatocellular carcinoma (HCC). The liver is uniquely susceptible to various forms of injury due to its central role in metabolism and detoxification, and understanding the molecular mechanisms underlying CLD is critical for developing effective interventions. One important aspect of this pathology is the dysregulation of liver-enriched transcription factors (LETFs), including hepatocyte nuclear factor (HNF) 4α and HNF1α, which are integral to maintaining hepatocyte function and overall liver homeostasis. **Objective:** This review aims to elucidate the multifaceted role of LETFs in chronic liver disease, with a specific focus on their correlations with clinical, biochemical, and histopathological parameters. By examining the existing literature, we seek to provide a comprehensive overview of the current understanding of LETFs and their implications for the diagnosis and treatment of CLD.

Material & Methods: A systematic literature review was conducted utilizing PubMed and other relevant biomedical databases, focusing on studies that examine LETF expression levels and their associations with CLD in human subjects. Key inclusion criteria included peer-reviewed articles published in English, studies involving adult populations, and research focusing on the roles of LETFs in various stages of liver disease.

Results: The findings from this review indicate that downregulation of LETFs, particularly in advanced stages of liver disease, correlates significantly with increased fibrosis and impaired liver function. This underscores their potential utility as diagnostic and prognostic markers in clinical practice.

Conclusions: Given their central role in liver function, LETFs may serve as valuable non-invasive biomarkers for assessing the progression of chronic liver disease and targets for therapeutic intervention. Further research is necessary to validate these findings and explore the clinical applicability of LETF modulation in the management of liver disease.

Keywords: Liver-enriched transcription factors, Chronic liver disease, Biomarkers, Hepatocyte nuclear factor, Chronic hepatitis, Cirrhosis, Hepatocellular carcinoma

INTRODUCTION

Chronic liver disease (CLD) encompasses a diverse range of hepatic conditions characterized by prolonged inflammation and liver injury. These conditions can arise from various etiologies, including viral hepatitis, alcohol consumption, non-alcoholic fatty liver disease (NAFLD), autoimmune liver disorders, and metabolic syndromes. The progression of CLD often leads to severe outcomes such as liver cirrhosis, which is defined by the replacement of healthy liver tissue with fibrotic scar tissue, disrupting normal liver architecture and function. This progression is associated with

significant morbidity and mortality, often manifesting as decompensated liver failure or hepatocellular carcinoma (HCC).[1]Hepatocyte nuclear factors (HNFs) are critical transcription factors that regulate the expression of genes involved in metabolism, detoxification, and cell differentiation. Key liver-enriched transcription factors (LETFs), including HNF4α, HNF1α, and CCAAT/enhancer-binding protein alpha (C/EBPα), are essential for maintaining hepatocyte function and overall liver homeostasis.[2,3] Dysregulation of these factors has been implicated in the pathogenesis of various liver diseases, making it imperative to investigate their roles in CLD.

2. Pathophysiology of Chronic Liver Disease

The pathophysiological mechanisms underlying chronic liver disease involve a complex interplay of cellular and molecular changes that ultimately lead to hepatocyte injury, inflammation, and fibrosis. Hepatocyte apoptosis, necrosis, and the release of pro-inflammatory cytokines play a significant role in the initiation and perpetuation of liver injury.[4] This injury is often exacerbated by the activation of hepatic stellate cells (HSCs), which undergo transdifferentiation into myofibroblast-like cells that secrete extracellular matrix components, contributing to fibrogenesis.[5] The progression from chronic hepatitis to cirrhosis involves extensive structural and functional changes in the liver, leading to altered blood flow, increased portal pressure, and, ultimately, liver dysfunction. LETFs are instrumental in regulating critical metabolic processes within hepatocytes; for instance, HNF4α is pivotal for gluconeogenesis, lipid metabolism, and the detoxification of xenobiotics.[6] Studies have shown that downregulation of LETFs, particularly HNF4α, is associated with advanced stages of liver disease, correlating with reduced liver function, increased fibrosis, and the activation of fibrogenic pathways, highlighting their importance in the pathogenesis of CLD.[7]

3. LETFs as Diagnostic and Prognostic Markers

Recent studies have demonstrated a significant correlation between LETF expression levels and various clinical indicators of liver function. For instance, decreased levels of HNF4α and HNF1α have been strongly associated with elevated fibrosis scores as measured by non-invasive techniques such as transient elastography and with deteriorating liver function tests, including aspartate aminotransferase (AST), alanine aminotransferase (ALT), and bilirubin levels.[8,9] Immunohistochemical analyses of liver biopsy specimens reveal that LETFs can be reliably quantified, with their expression levels correlating with histological severity as determined by the Metavir scoring system and other fibrosis assessment tools.[10] Moreover, emerging evidence suggests that circulating levels of LETFs, particularly HNF4α, may serve as promising non-invasive biomarkers for assessing CLD severity, offering a potential avenue for early diagnosis and monitoring of disease progression in a clinical setting.[11] The ability to measure LETFs in serum or plasma could significantly enhance the management of patients with CLD by facilitating timely interventions and potentially improving patient outcomes.

4. Methodologies for LETF Detection

Detection and quantification of LETFs can be accomplished using a variety of methodologies, including real-time polymerase chain reaction (RT-PCR) for assessing mRNA levels and immunohistochemistry (IHC) for visualizing protein localization within liver tissues.[12] RT-PCR enables the assessment of transcriptional activity and provides insights into the regulation of LETFs in response to liver injury. Meanwhile, IHC allows for spatial context regarding protein expression and can reveal changes in LETF localization in different liver disease states.[13] However, the variability in sample preparation, assay conditions, and patient demographics presents significant challenges in standardizing these methods across studies.[14] Comparative studies have shown a gradient of LETF expression across different stages of liver disease, with significant reductions noted in cirrhotic patients compared to those with early fibrosis or steatosis. This highlights the potential for LETFs to serve as valuable biomarkers for clinical practice.[15]In addition to traditional methodologies, emerging technologies such as mass spectrometry and next-generation sequencing offer promising avenues for more precise detection and quantification of LETFs in clinical samples.

5. Therapeutic Implications of LETFs

The restoration of LETF expression, particularly HNF4α, presents a promising therapeutic strategy to enhance hepatocyte function and counteract fibrosis in patients with chronic liver disease. Preclinical studies have demonstrated that HNF4α re-expression can ameliorate liver function, improve metabolic profiles, and reverse fibrotic changes in animal models of liver disease.[16] Strategies to enhance the expression or activity of LETFs could include pharmacological agents, gene therapy, or dietary interventions designed to modulate hepatic metabolism. For example, the use of small molecules to activate HNF4α or gene delivery techniques to restore its expression in hepatocytes is being actively explored.[17,18] Furthermore, the modulation of LETFs may also have implications for the treatment of associated conditions such as metabolic syndrome and diabetes, given the interconnected nature of liver function and systemic metabolism. Future research should focus on elucidating the specific signaling pathways through which LETFs exert their effects and identifying potential therapeutic targets for modulation in chronic liver disease management.

CONCLUSION

Liver-enriched transcription factors play a critical role in the pathophysiology of chronic liver disease,

serving as potential biomarkers and therapeutic targets. Their correlations with disease severity and progression underscore the importance of further investigation to validate their clinical utility and explore their applications in targeted therapies for liver disease. Understanding the intricate relationships between LETFs, liver function, and disease progression will be essential for developing innovative diagnostic and therapeutic strategies aimed at improving outcomes for patients suffering from chronic liver conditions.

REFERENCES

1. Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol. 2023 Aug;79(2):516-537.
2. Liu YB, Chen MK. Epidemiology of liver cirrhosis and associated complications: Current knowledge and future directions. World J Gastroenterol. 2022 Nov 7;28(41):5910-5930.
3. Costa RH, Kalinichenko VV, Holterman AXL, Wang X. Transcription factors in liver development, differentiation, and regeneration. Hepatology. 2003;38(6):1451-67.
4. Kanda T, Goto T, Hirotsu Y, Moriyama M, Omata M. Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review. Int J Mol Sci. 2019 Mar 18;20(6):1358.
5. Zhou WC, Zhang QB, Qiao L. Pathogenesis of liver cirrhosis. World J Gastroenterol. 2014 Jun 21;20(23):7312-24.
6. Morio B, Panthu B, Bassot A, Rieusset J. Role of mitochondria in liver metabolic health and diseases. Cell Calcium. 2021 Mar; 94:102336.
7. Caligiuri A, Gentilini A, Pastore M, Gitto S, Marra F. Cellular and Molecular Mechanisms Underlying Liver Fibrosis Regression. Cells. 2021 Oct 15;10(10):2759.
8. Yeh MM, Bosch DE, Daoud SS. Role of hepatocyte nuclear factor 4-alpha in gastrointestinal and liver diseases. World J Gastroenterol. 2019 Aug 14;25(30):4074-4091.
9. Huck I, Morris EM, Thyfault J, Apte U. Hepatocyte-Specific Hepatocyte Nuclear Factor 4 Alpha (HNF4) Deletion Decreases Resting Energy Expenditure by Disrupting Lipid and Carbohydrate Homeostasis. Gene Expr. 2021 Jun 11;20(3):157-168.
10. Neshat SY, Quiroz VM, Wang Y, Tamayo S, Doloff JC. Liver Disease: Induction, Progression, Immunological Mechanisms, and Therapeutic Interventions. Int J Mol Sci. 2021 Jun 24;22(13):6777.
11. Nallagangula KS, Nagaraj SK, Venkataswamy L, Chandrappa M. Liver fibrosis: a compilation on the biomarkers status and their significance during disease progression. Future Sci OA. 2017 Oct 5;4(1): FSO250.
12. Chan YT, Zhang C, Wu J, Lu P, Xu L, Yuan H, Feng Y, Chen ZS, Wang N. Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma. Mol Cancer. 2024 Sep 6;23(1):189.
13. Sharma A, Nagalli S. Chronic Liver Disease. [Updated 2023 Jul 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554597/
14. Kim WR. Clinical implications of short-term variability in liver function test results. Gastroenterology. 2008;135(3):1010-1.
15. How to cite this article: Parate T, Chavan P, Parate R. A clinical study of spectrum of liver diseases in alcoholic with respect to predictors of severity and prognosis. Vidarbha J Intern Med 2022; 32:100-7.
16. Yang T, Poenisch M, Khanal R, Hu Q, Dai Z, Li R, Song G, Yuan Q, Yao Q, Shen X, Taubert R, Engel B, Jaeckel E, Vogel A, Falk CS, Schambach A, Gerovska D, Araúzo-Bravo MJ, Vondran FWR, Cantz T, Horscroft N, Balakrishnan A, Chevessier F, Ott M, Sharma AD. Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model. J Hepatol. 2021 Dec;75(6):1420-1433.
17. Diaz-Aragon R, Coard MC, Amirneni S, Faccioli L, Haep N, Malizio MR, Motomura T, Kocas-Kilicarslan ZN, Ostrowska A, Florentino RM, Frau C. Therapeutic Potential of HNF4α in End-stage Liver Disease. Organogenesis. 2021 Oct 2;17(3-4):126-135.
18. Xu Y, Zhu Y, Hu S, Xu Y, Stroup D, Pan X, Bawa FC, Chen S, Gopoju R, Yin L, Zhang Y. Hepatocyte Nuclear Factor 4α Prevents the Steatosis-to-NASH Progression by Regulating p53 and Bile Acid Signaling (in mice). Hepatology. 2021 Jun;73(6):2251-2265.